Table_1_Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review.docx

Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months.

肝内淋巴上皮瘤样胆管癌（LELCC）是一种起源于胆管上皮的罕见恶性肿瘤。截至目前，学界关于肝内淋巴上皮瘤样胆管癌的影像学特征、临床病理特征及治疗策略的相关研究证据仍较为匮乏，全球范围内报道的EB病毒（EBV）阴性的肝内淋巴上皮瘤样胆管癌病例不足28例，其临床治疗方案仍有待深入探索。本研究报告2例EB病毒阴性的肝内淋巴上皮瘤样胆管癌患者病例，上述患者均接受了肝切除术、化疗与免疫治疗并获得较长生存周期：患者首先接受肿瘤切除手术，随后采用GS方案行辅助化疗，并联合自然杀伤细胞-细胞因子诱导的杀伤细胞（NK-CIK）及纳武利尤单抗实施免疫治疗。两名患者均获得了良好预后，生存时间分别超过100个月与85个月。